DHR vs. RVMD: Danaher vs. Revolution Medicines Stock Comparison

Company Profile

Danaher (DHR) and Revolution Medicines (RVMD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but DHR is classified in Life Sciences Tools & Services while RVMD is classified in Biotechnology.

Danaher (DHR) has more than two decades of public-market history since December 29, 1978, whereas Revolution Medicines (RVMD) listed on February 13, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Danaher (DHR) reports 8.19%, ranking against industry peers normally.

Danaher (DHR) at 16.91% retains a top-quartile share of revenue as profit, ahead of Revolution Medicines (RVMD) at 0.00%, which keeps about the industry-typical share.

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Danaher (DHR) reports 21.13%, ranking against industry peers normally.

Profitability Metrics

Growth

Only one side can be read here: Danaher (DHR) reports revenue growth of 2.90%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Only one side can be read here: Danaher (DHR) reports EPS growth of -4.54%, ranked against its industry; Revolution Medicines (RVMD) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Revolution Medicines (RVMD) at 8.36 keeps current ratio within its industry’s typical mid-range, while Danaher (DHR) at 1.63 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for DHR.

Both Danaher (DHR) at 0.52 and Revolution Medicines (RVMD) at 0.50 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Revolution Medicines (RVMD) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a yield of 0.67%, ranking against industry peers normally.

Revolution Medicines (RVMD) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a payout of 25.17%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Danaher (DHR) trades at 38.12 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

Danaher (DHR) at 6.32 prices around its industry’s typical P/S ratio, while Revolution Medicines (RVMD) at 210.51 clears its benchmark range — RVMD looks notably rich on sales.

Danaher (DHR) at 3.02 sits near its industry’s typical P/B ratio, while Revolution Medicines (RVMD) at 17.31 prices above its benchmark range — RVMD looks rich relative to book.

Valuation Metrics